Coronary heart disease
Conditions
Interventions
ACS group vs. Stable CAD group:N/A
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years; 2. Coronary angiography confirmed at least one coronary artery stenosis >50%. 3. or at least one troponin increase or decrease value > 99% of the upper limit of the reference value, accompanied by at least one of the following: (1) Symptoms of ischemia; (2) New ST segment and T wave changes or ECG showing new left bundle branch block; (3) ECG shows pathological Q wave progression; (4) Imaging evidence shows reduced myocardial contraction or abnormal local wall contraction. 4. Or a dose-loaded dual antiplatelet drug (ASA 300mg + clopidogrel 300mg) has been given before PCI.
Exclusion criteria
Exclusion criteria: 1. Combined with severe heart valve disease. 2. Combined with severe congenital heart disease. 3. Combined with hyperdynamic heart disease such as hyperthyroidism and anemia. 4. Combined with pulmonary heart disease. 5. Combined with hypertrophic obstructive cardiomyopathy. 6. Severe hypotension (SBP 160 mm Hg, and / or DBP > 100 mm Hg). 8. Hepatic insufficiency (defined as ALT or total bilirubin greater than 3 times the upper limit of normal). 9. Renal dysfunction (defined as serum creatinine greater than 1.5 times the upper limit of normal). 10. Patients at high risk of bleeding, such as thrombocytopenia, blood system diseases, etc. 11. Active peptic ulcer and skin ulcers. 12. Patients who are allergic to clopidogrel, ticagrelor, and aspirin. 13. Patients with a history of cardiogenic shock within two weeks. 14. Pregnant and lactating women, women of childbearing age who are not strictly contraceptive during treatment. 15. Those who do not have legal capacity or limited legal capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all-cause mortality (ACM) and cardiac mortality (CM); | — |
Secondary
| Measure | Time frame |
|---|---|
| Stroke, BARC level 2 or higher bleeding events, rehospitalization, and major cardiac adverse events (MACE) included all-cause death, stent thrombosis, cardiac death, target vessel revascularization, and stent thrombosis.; | — |
Countries
China
Contacts
Public ContactXiang Xie
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed